AMEDIKA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 266,267 | 259,957 | 256,367 | 336,551 | 287,276 | 418,554 | 413,408 | 443,783 |
| Profit before tax | 16,135 | -7,714 | 7,377 | 27,326 | -7,557 | 29,058 | 19,562 | 7,761 |
| Net profit | 15,305 | -7,714 | 7,258 | 23,172 | -7,557 | 25,812 | 16,615 | 6,485 |
| Equity | 79,975 | 72,261 | 79,519 | 102,691 | 95,134 | 120,923 | 125,774 | 116,377 |
| Liabilities | 7,652 | 33,877 | 47,190 | 56,329 | 33,408 | 57,074 | 58,407 | 87,203 |
| Non-current assets | 15,915 | 35,853 | 30,155 | 47,455 | 54,438 | 66,352 | 49,108 | 33,885 |
| Current assets | 79,789 | 78,636 | 105,286 | 119,710 | 73,680 | 111,677 | 133,495 | 168,223 |
| Total assets | 95,704 | 114,489 | 135,441 | 167,165 | 128,118 | 178,029 | 182,603 | 202,108 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 9,211 | 17,669 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +2.6% | -2.4% | -1.4% | +31.3% | -14.6% | +45.7% | -1.2% | +7.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 16.0% | -6.7% | 5.4% | 13.9% | -5.9% | 14.5% | 9.1% | 3.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 19.1% | -10.7% | 9.1% | 22.6% | -7.9% | 21.3% | 13.2% | 5.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.7% | -3.0% | 2.8% | 6.9% | -2.6% | 6.2% | 4.0% | 1.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.1% | -3.0% | 2.9% | 8.1% | -2.6% | 6.9% | 4.7% | 1.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.5 | 0.6 | 0.5 | 0.4 | 0.5 | 0.5 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 133,134 | 129,979 | 128,184 | 168,276 | 143,638 | 209,277 | 206,704 | 221,892 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
AMEDIKA - Social security debts
The company had no debts to Sodra
AMEDIKA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-14 | 2025-01-14 | 702.36 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
AMEDIKA, UAB (company code 302478913) is a Private Limited Liability Company operating in wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €443.8K and net profit of €6.5K, with a profit margin of 1.5%. Revenue increased by 7.3% year on year and by 6.0% over two years, showing moderate top-line growth, while profitability weakened over the same period. Net profit declined from €25.8K in 2023 to €16.6K in 2024 and €6.5K in 2025, alongside a fall in profit margin from 6.2% to 4.0% and then to 1.5%. At the end of 2025, total assets stood at €202.1K, equity at €116.4K, and liabilities at €87.2K. The equity ratio was 57.6% and debt-to-equity 0.75, indicating a balanced capital structure. Asset turnover reached 2.20x, ROE was 5.6%, and ROA was 3.2%. Revenue per employee was €221.9K, with profit per employee of €3.2K.